The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations

Bibliography

• COTZIAS GC, VAN WOERT MH, SCHIFFER LM: Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. (1967) 276:374.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, AGID Y, MIZUNO Y et al.: Levodopa in the treatment of Parkinson’s disease: current controversies. Mov. Disord. (2004) 19(9):997.
   PubMed Web of Science ®Google Scholar
• HOEHN MM: The natural history of Parkinson’s disease in the pre-levodopa and post-levodopa eras. Neurol. Clin. (1992) 10(2):331-339.
   PubMed Web of Science ®Google Scholar
• UITTI RJ, AHLSKOG JE, MARAGANORE DM et al.: Levodopa therapy and survival in idiopathic Parkinson’s disease: Olmsted County project. Neurology (1993) 43(10):1918-1926.
   PubMed Web of Science ®Google Scholar
• MERCURI NB, BERNARDI G: The ‘magic’ of L-dopa: why is it the gold standard Parkinson’s disease therapy? Trends Pharmacol. Sci. (2005) 26(7):341-344.
   PubMed Web of Science ®Google Scholar
• SCHRAG A, QUINN N: Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain (2000) 123(Pt. 11):2297-2305.
   PubMed Web of Science ®Google Scholar
• KURLAN R: ‘Levodopa phobia’: a new iatrogenic cause of disability in Parkinson’s disease.’ Neurology (2005) 64(5):923-924.
   PubMed Web of Science ®Google Scholar
• CHASE TN, OH JD: Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol. (2000) 47(4 Suppl. 1):S122-S130.
   PubMedGoogle Scholar
• OLANOW W, SCHAPIRA AH, RASCOL O: Continuous dopamine-receptor stimulation in early Parkinson’s disease. Trends Neurosci. (2000) 23(10 Suppl.):S117-S126.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, VACCA L, BERARDELLI A et al.: Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life. Mov. Disord. (2001) 16(2):301-305.
   PubMed Web of Science ®Google Scholar
• MUENTER MD, TYCE GM: L-dopa therapy of Parkinson’s disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin. Proc. (1971) 46(4):231-239.
   PubMed Web of Science ®Google Scholar
• FAHN S, OAKES D, SHOULSON I et al.: Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med. (2004) 351(24):2498-2508.
   PubMed Web of Science ®Google Scholar
• NUTT JG: On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann. Neurol. (1987) 22(4):535-540.
   PubMed Web of Science ®Google Scholar
• FABBRINI G, MOURADIAN MM, JUNCOS JL et al.: Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, Part I. Ann. Neurol. (1988) 24(3):366-371.
   PubMed Web of Science ®Google Scholar
• MOURADIAN MM, JUNCOS JL, FABBRINI G et al.: Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, Part II. Ann. Neurol. (1988) 24(3):372-378.
   PubMed Web of Science ®Google Scholar
• ZAPPIA M, OLIVERI RL, MONTESANTI R et al.: Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology (1999) 52(4):763-767.
   PubMed Web of Science ®Google Scholar
• NUTT JG: Levodopa-induced dyskinesia: review, observations, and speculations. Neurology (1990) 40(2):340-345.
   PubMed Web of Science ®Google Scholar
• WOITALLA D, GOETZE O, KIM JI et al.: Levodopa availability improves with progression of Parkinson’s disease. J. Neurol. (2006) in press.
   Google Scholar
• BARBATO L, STOCCHI F, MONGE A et al.: The long-duration action of levodopa may be due to a postsynaptic effect. Clin. Neuropharmacol. (1997) 20(5):394-401.
   PubMedGoogle Scholar
• BRAVI D, MOURADIAN MM, ROBERTS JW et al.: Wearing-off fluctuations in Parkinson’s disease: contribution of postsynaptic mechanisms. Annals of Neurology (1994) 36:27-31.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, NORDERA G, MARSDEN CD: Strategies for treating patients with advanced Parkinson’s disease with disastrous fluctuations and dyskinesias. Clin. Neuropharmacol. (1997) 20(2):95-115.
   PubMed Web of Science ®Google Scholar
• OBESO JA, RODRIGUEZ-OROZ MC, CHANA P et al.: The evolution and origin of motor complications in Parkinson’s disease. Neurology (2000) 55(11 Suppl. 4):S13-S23.
   PubMedGoogle Scholar
• SAGE JI, MARK MH: Basic mechanisms of motor fluctuations. Neurology (1994) 44(7 Suppl. 6):S10-S14.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: Pramipexole versus levodopa as initial treatment for Parkinson’s disease: a randomized controlled trial. Parkinson Study Group. JAMA (2000) 284(15):1931-1938.
   PubMedGoogle Scholar
• LIEBERMAN A, VIJAY M: Wearing-off of greatest concern for PD patient. Eur J. Neurol. (2004) 11:S36-S182.
   Google Scholar
• ADLER CH: Relevance of motor complications in Parkinson’s disease. Neurology (2002) 58(4 Suppl. 1):S51-S56.
   PubMed Web of Science ®Google Scholar
• STOCCHI F: Disorders of bowel function in Parkinsonism. In: Neurology of Bladder, Bowel, and Sexual Dysfunction. Fowler C (ed.) Butterworth Heinemann, Boston (1999):255-264.
   Google Scholar
• NUTT JG, WOODWARD WR, HAMMERSTAD JP et al.: The ‘on-off’ phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. N. Engl. J. Med. (1984) 310(8):483-488.
   PubMed Web of Science ®Google Scholar
• NUTT JG, WOODWARD WR, CARTER JH et al.: Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J. Neurol. Neurosurg. Psychiatry (1989) 52(4):481-487.
   PubMed Web of Science ®Google Scholar
• DJALDETTI R, BARON J, ZIV I et al.: Gastric emptying in Parkinson’s disease: patients with and without response fluctuations. Neurology (1996) 46(4):1051-1054.
   PubMed Web of Science ®Google Scholar
• AHLSKOG JE, MUENTER MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. (2001) 16(3):448-458.
   PubMed Web of Science ®Google Scholar
• RAJPUT AH, FENTON ME, BIRDI S et al.: Clinical-pathological study of levodopa complications. Mov. Disord. (2002) 17(2):289-296.
   PubMed Web of Science ®Google Scholar
• FAHN S: Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J. Neurol. (2005) 252(Suppl. 4):iv37-iv42.
   PubMed Web of Science ®Google Scholar
• STACY M, A BOWRON et al.: Identification of motor and nonmotor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov. Disord. (2005) 20:726-733.
   PubMed Web of Science ®Google Scholar
• GROSSET KA, BONE I, GROSSET DG: Suboptimal medication adherence in Parkinson’s disease. Mov. Disord. (2005) 20(11):1502-1507.
   PubMed Web of Science ®Google Scholar
• GROSSET KA, REID JL, GROSSET DG: Medicine-taking behavior: implications of suboptimal compliance in Parkinson’s disease. Mov. Disord. (2005) 20(11):1397-1404.
   PubMed Web of Science ®Google Scholar
• LEOPOLD NA, POLANSKY M, HURKA MR: Drug adherence in Parkinson’s disease. Mov. Disord. (2004) 9(5):513-517.
   Google Scholar
• PAHWA R, BUSENBARK K, HUBER SJ et al.: Clinical experience with controlled-release carbidopa/levodopa in Parkinson’s disease. Neurology (1993) 43(4):677-681.
   PubMedGoogle Scholar
• KOLLER WC, PAHWA R: Treating motor fluctuations with controlled-release levodopa preparations. Neurology (1994) 44(7 Suppl. 6):S23-S28.
   PubMed Web of Science ®Google Scholar
• KOLLER WC, HUTTON JT, TOLOSA E et al.: Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology (1999) 53(5):1012-1019.
   PubMed Web of Science ®Google Scholar
• YEH KC, AUGUST TF, BUSH DF: Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology (1989) 39(Suppl. 2):25-38.
   PubMed Web of Science ®Google Scholar
• MOVEMENT DISORDER SOCIETY TASKFORCE: Management of Parkinson’s disease: an evidence based review. Mov. Disord. (2002) 17(Suppl. 4):S1-S166.
   PubMedGoogle Scholar
• STOCCHI F: Managing the critical problems of advanced Parkinson’s disease. Expert Rev. Neurotherapeutics (2002) 2(6):835-847.
   PubMedGoogle Scholar
• NYHOLM D, LENNERNAS H, GOMES-TROLIN C et al.: Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson’s disease on individual drug combinations. Clin. Neuropharmacol. (2002) 25(2):89-96.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, BERARDELLI A, VACCA L et al.: Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson’s disease. Clin. Neuropharmacol. (2003) 26(3):151-155.
   PubMed Web of Science ®Google Scholar
• DUPONT E, ANDERSEN A, BOAS J et al.: Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol. Scand. (1996) 93(1):14-20.
   PubMed Web of Science ®Google Scholar
• KURTH MC, TETRUD JW, TANNER CM et al.: Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson’s disease patients with ‘on-off’ fluctuations. Neurology (1993) 43(9):1698-1703.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, VACCA L, RUGGIERI S et al.: Intermittent versus continuous levodopa administration in patients with advanced Parkinson’s disease: a clinical and pharmacokinetic study. Arch. Neurol. (2005) 62(6):905-910.
   PubMed Web of Science ®Google Scholar
• NUTT JG, CARTER JH, LEA ES et al.: Motor fluctuations during continuous levodopa infusions in patients with Parkinson’s disease. Mov. Disord. (1997) 12(3):285-292.
   PubMed Web of Science ®Google Scholar
• NILSSON D, HANSSON LE, JOHANSSON K et al.: Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol. Scand. (1998) 97(3):175-183.
   PubMed Web of Science ®Google Scholar
• SYED N, MURPHY J, ZIMMERMAN T et al.: Ten years’ experience with enteral levodopa infusions for motor fluctuations in Parkinson’s disease. Mov. Disord. (1998) 13(2):336-338.
   PubMed Web of Science ®Google Scholar
• NYHOLM D, JANSSON R, WILLOWS T et al.: Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology (2005) 65:1506-1507.
   PubMed Web of Science ®Google Scholar
• NYHOLM D, NILSSON REMAHL AI, DIZDAR N et al.: Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson’s disease. Neurology (2005) 64:216-223.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, OLANOW CW: Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology (2004) 62(1 Suppl. 1):S56-S63.
   PubMed Web of Science ®Google Scholar
• Tolcapone: new drug. In: Parkinson’s disease: unacceptable risk of severe hepatitis. Prescrire Int. (2006) 15(82):54-57.
   Google Scholar
• POEWE W: The role of COMT inhibition in the treatment of Parkinson’s disease. Neurology (2004) 62(1 Suppl. 1):S31-S38.
   PubMed Web of Science ®Google Scholar
• KAAKKOLA S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease. Drugs (2000) 59(6):1233-1250.
   PubMed Web of Science ®Google Scholar
• RUOTTINEN HM, RINNE UK: Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J. Neurol. Neurosurg. Psychiatry (1996) 60(1):36-40.
   PubMed Web of Science ®Google Scholar
• NUTT JG, WOODWARD WR, BECKNER RM et al.: Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology (1994) 44(5):913-919.
   PubMed Web of Science ®Google Scholar
• GORDIN A, KAAKKOLA S, TERAVAINEN H: Clinical advantages of COMT inhibition with entacapone – a review. J. Neural Transm. (2004) 111(10-11):1343-1363.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, BARBATO L, NODERA G et al.: Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson’s patients. J. Neural Transm. (2004) 111(2):173-80.
   PubMed Web of Science ®Google Scholar
• GERLACH M, VAN DEN BUUSE M, BLAHA C et al.: Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat. Naunyn Schmiedebergs Arch. Pharm. (2004) 370(5):388-394.
   PubMed Web of Science ®Google Scholar
• SAWLE GV, BURN DJ, MORRISH PK et al.: The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson’s disease. Neurology (1994) 44(7):1292-1297.
   PubMed Web of Science ®Google Scholar
• PARKINSONS STUDY GROUP: Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Parkinson Study Group. Ann. Neurol. (1997) 42(5):747-755.
   PubMed Web of Science ®Google Scholar
• RINNE UK, LARSEN JP, SIDEN A et al.: Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology (1998) 51(5):1309-1314.
   PubMed Web of Science ®Google Scholar
• MYLLYLA V, KULTALAHTI ER, HAAPANIEMI H et al.: Twelve-month safety of entacapone in patients with Parkinson’s disease. Eur J. Neurol. (2001) 8(1):53-60.
   PubMed Web of Science ®Google Scholar
• POEWE WH, DEUSCHL G, GORDIN A et al.: Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol. Scand. (2002) 105(4):245-255.
   PubMed Web of Science ®Google Scholar
• BROOKS DJ, SAGAR H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study. J. Neurol. Neurosurg. Psychiatry (2003) 74(8):1071-1079.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, BATTAGLIA G, VACCA L et al.: Clinical models of continuous dopaminergic stimulation. Neurology (2004) 19(Suppl. 9):S435.
   Google Scholar
• MÜLLER T, ERDMANN C, MUHLACK S et al.: Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov. Disord. (2005) Epub ahead of print.
   Google Scholar
• MARIN C, AGUILAR E, BONASTRE M et al.: Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp. Neurol. (2005) 192(1):184-193.
   Web of Science ®Google Scholar
• SMITH LA, JACKSON MJ, AL-BARGHOUTHY G et al.: Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Disord. (2004) 20(3):306-314.
   Google Scholar